189 related articles for article (PubMed ID: 38038261)
1. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma.
Webking S; Sandoval ML; Chuong MD; Ucar A; Aparo S; De Zarraga F; Sahin I; Biachi T; Kim DW; Hoffe SE; Frakes JM; Palm RF
Cancer Control; 2023; 30():10732748231219069. PubMed ID: 38038261
[TBL] [Abstract][Full Text] [Related]
2. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART).
Bryant JM; Palm RF; Herrera R; Rubens M; Hoffe SE; Kim DW; Kaiser A; Ucar A; Fleming J; De Zarraga F; Hodul P; Aparo S; Asbun H; Malafa M; Jimenez R; Denbo J; Frakes JM; Chuong MD
Cancer Control; 2023; 30():10732748221150228. PubMed ID: 36598464
[TBL] [Abstract][Full Text] [Related]
3. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
Parikh PJ; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Pfeffer MR; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Chuong MD
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):799-808. PubMed ID: 37210048
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study.
Chuong MD; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Raphael Pfeffer M; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Jitendra Parikh P
Radiother Oncol; 2024 Feb; 191():110064. PubMed ID: 38135187
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
Onal C; Gultekin M; Oymak E; Guler OC; Yilmaz MT; Yuce Sari S; Akkus Yildirim B; Yildiz F
Int J Gynecol Cancer; 2020 Jun; 30(6):865-872. PubMed ID: 32273293
[TBL] [Abstract][Full Text] [Related]
9. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
[TBL] [Abstract][Full Text] [Related]
10. Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer.
Chuong MD; Herrera R; Kaiser A; Rubens M; Romaguera T; Alvarez D; Kotecha R; Hall MD; McCulloch J; Ucar A; DeZarraga F; Aparo S; Joseph S; Asbun H; Jimenez R; Narayanan G; Gutierrez AN; Mittauer KE
Front Oncol; 2022; 12():888462. PubMed ID: 35814383
[TBL] [Abstract][Full Text] [Related]
11. Causes of Death Among Patients With Initially Inoperable Pancreas Cancer After Induction Chemotherapy and Ablative 5-fraction Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy.
Chuong MD; Herrera R; Ucar A; Aparo S; De Zarraga F; Asbun H; Jimenez R; Asbun D; Narayanan G; Joseph S; Kotecha R; Hall MD; Mittauer KM; Alvarez D; McCulloch J; Romaguera T; Gutierrez A; Kaiser A
Adv Radiat Oncol; 2023; 8(1):101084. PubMed ID: 36483070
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report.
Doty DG; Chuong MD; Gomez AG; Bryant J; Contreras J; Romaguera T; Alvarez D; Kotecha R; Mehta MP; Gutierrez AN; Mittauer KE
Med Dosim; 2021 Winter; 46(4):384-388. PubMed ID: 34120803
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
König L; Häfner MF; Katayama S; Koerber SA; Tonndorf-Martini E; Bernhardt D; von Nettelbladt B; Weykamp F; Hoegen P; Klüter S; Susko MS; Debus J; Hörner-Rieber J
Radiat Oncol; 2020 Feb; 15(1):30. PubMed ID: 32019553
[TBL] [Abstract][Full Text] [Related]
14. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic radiotherapy in the management of oligometastatic and recurrent head and neck cancer: a single-center experience.
Mohamed AA; Goncalves M; Singh BP; Tometten M; Rashad A; Hölzle F; Hackenberg S; Eble M
Strahlenther Onkol; 2024 May; 200(5):400-408. PubMed ID: 38063900
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT.
Gkika E; Adebahr S; Kirste S; Schimek-Jasch T; Wiehle R; Claus R; Wittel U; Nestle U; Baltas D; Grosu AL; Brunner TB
Strahlenther Onkol; 2017 Jun; 193(6):433-443. PubMed ID: 28138949
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
18. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
[TBL] [Abstract][Full Text] [Related]
19. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer.
Chuong MD; Bryant J; Mittauer KE; Hall M; Kotecha R; Alvarez D; Romaguera T; Rubens M; Adamson S; Godley A; Mishra V; Luciani G; Gutierrez AN
Pract Radiat Oncol; 2021; 11(2):134-147. PubMed ID: 32947042
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
